PH-231
Not Specified (Melanin production-related)
DiscoveryEarly Research
Key Facts
Indication
Not Specified (Melanin production-related)
Phase
Discovery
Status
Early Research
Company
About Phio Pharmaceuticals
Phio Pharmaceuticals leverages its proprietary INTASYL self-delivering siRNA technology to develop next-generation immuno-oncology therapeutics. Co-founded by Nobel laureate Craig Mello, the company is advancing a clinical-stage pipeline targeting proteins like PD-1 and BRD4 to enhance anti-tumor immunity. With a strategic pivot from discovery to development under new leadership, Phio is focused on key initiatives in cutaneous squamous cell carcinoma and melanoma, aiming to overcome limitations of current immunotherapies.
View full company profile